Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02194075

Enrollment

Registered

2014-07-18

Start date

2013-10-31

Completion date

2015-10-31

Last updated

2015-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder

Brief summary

Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.

Interventions

DRUGFluvoxamine+Methylphenidate hydrochloride

DRUGFluvoxamine+sugar pill

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Informed consent * Met DSM-V criteria * Y-BOCS ≥ 16 * Course of illness ≥ 1year * Age range between 18\ 40 years old * Junior high school education level above

Exclusion criteria

* Any other psychiatric axis-I or axis-II disorders * History of epileptic seizures or any other neurological disorder * Any other clinically relevant abnormalities in their medical history or laboratory examinations; alcohol or drug abuser

Design outcomes

Primary

Measure	Time frame
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)	8 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026